Waldenstrom's macroglobulinemia: clinical features, complications, and management
MA Dimopoulos, P Panayiotidis… - Journal of Clinical …, 2000 - ascopubs.org
PURPOSE: To review the clinical features, complications, and treatment of Waldenström's
macroglobulinemia, a low-grade lymphoproliferative disorder that produces monoclonal …
macroglobulinemia, a low-grade lymphoproliferative disorder that produces monoclonal …
Diagnosis and management of Waldenstrom's macroglobulinemia
MA Dimopoulos, RA Kyle… - Journal of clinical …, 2005 - ascopubs.org
Purpose To review the diagnostic criteria, prognostic factors, response criteria, and
treatment options of patients with Waldenstrom's macroglobulinemia (WM). Methods A …
treatment options of patients with Waldenstrom's macroglobulinemia (WM). Methods A …
[图书][B] DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology
VT DeVita, TS Lawrence, SA Rosenberg - 2008 - books.google.com
Acclaimed by the worldwide medical community as" a staple reference text in the medical
oncologist's library"(JAMA), DeVita, Hellman, and Rosenberg's Cancer: Principles and …
oncologist's library"(JAMA), DeVita, Hellman, and Rosenberg's Cancer: Principles and …
Treatment of older patients with mantle-cell lymphoma
HC Kluin-Nelemans, E Hoster, O Hermine… - … England Journal of …, 2012 - Mass Medical Soc
Background The long-term prognosis for older patients with mantle-cell lymphoma is poor.
Chemoimmunotherapy results in low rates of complete remission, and most patients have a …
Chemoimmunotherapy results in low rates of complete remission, and most patients have a …
Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial
HC Kluin-Nelemans, E Hoster, O Hermine… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE In an update of the randomized, open-label, phase III European Mantle Cell
Lymphoma (MCL) Elderly trial (ClinicalTrials. gov identifier: NCT00209209), published in …
Lymphoma (MCL) Elderly trial (ClinicalTrials. gov identifier: NCT00209209), published in …
Waldenström macroglobulinemia
A Vijay, MA Gertz - Blood, the Journal of the American Society …, 2007 - ashpublications.org
In the past 36 months, new developments have occurred both in the understanding of the
biology of Waldenström macroglobulinemia (WM) and in therapeutic options for WM. Here …
biology of Waldenström macroglobulinemia (WM) and in therapeutic options for WM. Here …
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
Waldenström macroglobulinemia is a B-cell malignancy with lymphoplasmacytic infiltration
in the bone marrow or lymphatic tissue and a monoclonal immunoglobulin M protein (IgM) in …
in the bone marrow or lymphatic tissue and a monoclonal immunoglobulin M protein (IgM) in …
Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment
The spectrum of plasma cell disorders is broad. Monoclonal gammopathy of undetermined
significance and smoldering multiple myeloma are asymptomatic disorders characterized by …
significance and smoldering multiple myeloma are asymptomatic disorders characterized by …
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical …
CI Chen, CT Kouroukis, D White, M Voralia… - Journal of clinical …, 2007 - ascopubs.org
Purpose To evaluate the efficacy and toxicity of single-agent bortezomib in Waldenström's
macroglobulinemia (WM). Patients and Methods Symptomatic WM patients, untreated or …
macroglobulinemia (WM). Patients and Methods Symptomatic WM patients, untreated or …
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
SP Treon, AR Branagan, L Ioakimidis… - Blood, The Journal …, 2009 - ashpublications.org
We report the long-term outcome of a multicenter, prospective study examining fludarabine
and rituximab in Waldenström macroglobulinemia (WM). WM patients with less than 2 prior …
and rituximab in Waldenström macroglobulinemia (WM). WM patients with less than 2 prior …